Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,959.00 GBX | -0.47% | +3.21% | +28.90% |
09-09 | BRITISH AMERICAN TOBACCO : Receives a Buy rating from Barclays | ZD |
09-09 | Barclays cuts Burberry to 'underweight' | AN |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 25.88B | 25.78B | 25.68B | 27.66B | 27.28B | |||||
Total Revenues | 25.88B | 25.78B | 25.68B | 27.66B | 27.28B | |||||
Cost of Goods Sold, Total | 4.44B | 4.14B | 4.6B | 4.8B | 4.89B | |||||
Gross Profit | 21.44B | 21.64B | 21.09B | 22.85B | 22.39B | |||||
Selling General & Admin Expenses, Total | 2.87B | 2.65B | 3.81B | 3.83B | 3.86B | |||||
Depreciation & Amortization - (IS) | 994M | 1.09B | 938M | 962M | 849M | |||||
Other Operating Expenses | 7.02B | 6.83B | 5.34B | 6.41B | 5.05B | |||||
Other Operating Expenses, Total | 10.89B | 10.57B | 10.09B | 11.2B | 9.75B | |||||
Operating Income | 10.55B | 11.07B | 11B | 11.65B | 12.64B | |||||
Interest Expense, Total | -1.76B | -1.81B | -1.5B | -1.66B | -1.86B | |||||
Interest And Investment Income | 84M | 50M | 35M | 92M | 186M | |||||
Net Interest Expenses | -1.68B | -1.76B | -1.47B | -1.57B | -1.67B | |||||
Income (Loss) On Equity Invest. | 498M | 455M | 415M | 442M | 585M | |||||
Currency Exchange Gains (Loss) | 457M | -225M | 171M | -491M | 432M | |||||
Other Non Operating Income (Expenses) | -380M | 234M | -166M | 324M | -623M | |||||
EBT, Excl. Unusual Items | 9.45B | 9.77B | 9.95B | 10.36B | 11.36B | |||||
Restructuring Charges | -565M | -408M | -150M | -774M | 2M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | -194M | -209M | -57M | - | -4.61B | |||||
Gain (Loss) On Sale Of Investments | - | - | -24M | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | -358M | 6M | -546M | |||||
Asset Writedown | -261M | - | -92M | -123M | -23.11B | |||||
Legal Settlements | -264M | -508M | -81M | -144M | -156M | |||||
Other Unusual Items | -252M | 25M | -26M | - | - | |||||
EBT, Incl. Unusual Items | 7.91B | 8.67B | 9.16B | 9.32B | -17.06B | |||||
Income Tax Expense | 2.06B | 2.11B | 2.19B | 2.48B | -2.87B | |||||
Earnings From Continuing Operations | 5.85B | 6.56B | 6.97B | 6.85B | -14.19B | |||||
Net Income to Company | 5.85B | 6.56B | 6.97B | 6.85B | -14.19B | |||||
Minority Interest | -145M | -164M | -173M | -180M | -178M | |||||
Net Income - (IS) | 5.7B | 6.4B | 6.8B | 6.67B | -14.37B | |||||
Preferred Dividend and Other Adjustments | - | - | 12M | 49M | 45M | |||||
Net Income to Common Incl Extra Items | 5.7B | 6.4B | 6.79B | 6.62B | -14.41B | |||||
Net Income to Common Excl. Extra Items | 5.7B | 6.4B | 6.79B | 6.62B | -14.41B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.5 | 2.8 | 2.97 | 2.93 | -6.47 | |||||
Basic EPS - Continuing Operations | 2.5 | 2.8 | 2.97 | 2.93 | -6.47 | |||||
Basic Weighted Average Shares Outstanding | 2.28B | 2.29B | 2.29B | 2.26B | 2.23B | |||||
Net EPS - Diluted | 2.49 | 2.79 | 2.96 | 2.92 | -6.47 | |||||
Diluted EPS - Continuing Operations | 2.49 | 2.79 | 2.96 | 2.92 | -6.47 | |||||
Diluted Weighted Average Shares Outstanding | 2.29B | 2.3B | 2.3B | 2.27B | 2.23B | |||||
Normalized Basic EPS | 2.52 | 2.6 | 2.64 | 2.79 | 3.11 | |||||
Normalized Diluted EPS | 2.51 | 2.59 | 2.63 | 2.78 | 3.11 | |||||
Dividend Per Share | 2.03 | 2.1 | 2.16 | 2.18 | 2.31 | |||||
Payout Ratio | 80.61 | 74.14 | 72.2 | 73.73 | -35.6 | |||||
American Depositary Receipts Ratio (ADR) | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |||||
Supplemental Items | ||||||||||
EBITDA | 11.54B | 12.16B | 11.94B | 12.18B | 13.28B | |||||
EBITA | 10.55B | 11.41B | 11B | 11.65B | 12.88B | |||||
EBIT | 10.55B | 11.07B | 11B | 11.65B | 12.64B | |||||
EBITDAR | 11.56B | - | 11.95B | 12.2B | 13.29B | |||||
Effective Tax Rate - (Ratio) | 26.07 | 24.31 | 23.89 | 26.58 | 16.83 | |||||
Current Domestic Taxes | 8M | 38M | -25M | -3M | 32M | |||||
Current Foreign Taxes | 2.05B | 2.39B | 2.4B | 2.72B | 2.78B | |||||
Total Current Taxes | 2.06B | 2.42B | 2.38B | 2.72B | 2.81B | |||||
Total Deferred Taxes | 8M | -317M | -187M | -240M | -5.68B | |||||
Normalized Net Income | 5.76B | 5.94B | 6.05B | 6.29B | 6.93B | |||||
Interest on Long-Term Debt | 32M | - | 24M | 25M | 30M | |||||
Non-Cash Pension Expense | 10M | - | -28M | -29M | -33M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | - | 1.24B | 1.16B | 1.15B | |||||
Selling and Marketing Expenses | - | - | 1.24B | 1.16B | 1.15B | |||||
Research And Development Expense From Footnotes | 376M | 307M | 304M | 323M | 408M | |||||
Net Rental Expense, Total | 17M | - | 9M | 12M | 14M | |||||
Imputed Operating Lease Interest Expense | 5.15M | - | 2.59M | 3.85M | 4.98M | |||||
Imputed Operating Lease Depreciation | 11.85M | - | 6.41M | 8.15M | 9.02M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 120M | - | 78M | 85M | - | |||||
Total Stock-Based Compensation | 120M | - | 78M | 85M | - |